BIOGRAPHICAL SKETCH

NAME	**POSITION TITLE**
Jeng Her	CEO AP Biosciences, Inc. 17F, No. 3, Park St., NanGang Dist., Taipei, Taiwan 115

EDUCATION/TRAINING

INSTITUTION AND LOCATION	DEGREE	WHEN	FIELD OF STUDY
Dept. of Physics, National Taiwan University, Taipei, Taiwan	B.S.	1981-1985	Physics
Dept. of Microbiology & Immunology, University of Virginia, Charlottesville, VA	Ph.D.	1987-1993	MAP kinase signal transduction
Bristol-Myers Squibb Research Institute (BMS), Princeton, NJ	Post-Doc	1993-1995	Protein kinases and G proteins
DNAX Research Institute (Schering-Plough Pharmaceuticals, subsequently acquired by Merck), Palo Alto, CA	Post-Doc	1995-1998	Signal transduction pathways of serine/threonine kinases

Professional experience

1998 - 2004 Co-founder of KaloBios Pharmaceuticals, Inc. (NASDAQ: KBIO), an antibody company developing three innovative antibody drugs in clinical trials for cancer, inflammatory and anti-infectious diseases; including KB001-A, an antibody for anti-Pseudomonas infection of patients on ventilator, which was licensed to Sanofi Pasteur for $290M plus royalties. In addition, the antibody Humaneering technology developed by the founders was licensed non-exclusively to Novartis for $32M in 2006. Total of ~ $100M venture capital was raised before the company went public in Jan, 2013.

2005 - 2006 A founding member and VP of R&D, Multispan, Inc., (California, USA) one of the leaders in G protein-coupled receptor (GPCR) specialty reagents and service provider for GPCR drug development. Dr. Jeng Her was responsible for developing ~ 100 human GPCR expression cell lines for functional assays, as well as a cell-based assay for GPCR compound profiling. These reagents and services had become the major revenue-generation mechanisms which brought the company to a break-even point 18 months after inception.

2006 - 2013 Founder & CEO of ProtevoBio, Inc. (California, USA) ProtevoBio is a self-support, employee-owned company with a focus on antibody and protein engineering for innovative antibodies and receptor/ligand Fc fusion traps. The company uses its fully integrated technology platform for generation and optimization of antibody/biologic drugs, including IBI302, a biologic for treatment of age-related macular degeneration. IBI302 was

licensed in June, 2012, to Innovent, Inc., a joint venture of Fidelity Biosciences and Lilly Ventures.

2013 – Present CEO of AP Biosciences, Inc. (Taipei, Taiwan)

Other Experience and Professional Membership

2007- 2012 Board member of the Chinese Bioscience Association, San Francisco, CA
2011 - Present Board Director of Pacgen Life Science Corp (CVE: PBS)
2013 – Present Board Director of AP Biosciences, Inc.

Issued Patents

1. Robert F Balint, Jeng-Horng Her: Reactivation-based molecular interaction sensors. Feb, 26 2008: US 7,335,478
2. Robert F Balint, Jeng-Horng Her: Methods for affinity maturation. Oct, 7 2008: US 7,432,063
3. Robert F Balint, Jeng-Horng Her: Circularly permutated, interaction-activated proteins. Jun, 9 2009: US 7,544,477
4. Helena S Mancebo, Jeng-Horng Her, Samuel X Li, Jianfu L Wang: GPCR-expressing cell lines. Aug, 24 2010: US 7,781,209
5. Peter Flynn, Kenneth Luehrsen, Robert F Balint, Jeng-Horng Her, Christopher R Bebbington, Geoffrey T Yarranton: Antibody specificity transfer using minimal essential binding determinants. Jul, 19 2011: US 7,981,843
6. Helen M Blau, Robert F Balint, Thomas S Wehrman, Jeng-Horng Her: Detection of molecular interactions by β-lactamase reporter fragment complementation. US 8,148,110
7. Helena S Mancebo, Jeng-Horng Her, Samuel X Li, Jianfu L Wang: GPCR expression vector. US 8,178,346
8. Balint, Robert F.; Luehrsen, Kenneth; Flynn, Peter; Yarranton, Geoffrey T.; Bebbington, Christopher R.; Her, Jeng-Horng. Antibody specificity transfer using minimal essential binding determinants. AU 2005207003

Patents Pending

1. Jeng-Horng Her and Huang-Tsu Chen. WO2013082563 – Protein inhibitors to complement and VEGF pathways and methods of use thereof
2. Robert F Balint and Jeng-Horng Her. WO2009079618 – ENZYME ENGINEERING SYSTEMS AND METHODS